Benefits
Faster stress recovery in healthy adults
Lactium at 150-300 mg/day reduces perceived stress and anxiety scores in healthy adults experiencing work or life stress. The signature finding is faster physiological recovery from stress — blood pressure and heart rate return to baseline more quickly after a stressful event. Effect is modest but consistent across multiple trials. Reasonable consideration for situational stress management; not a replacement for clinical anxiety treatment when symptoms are severe or persistent.
Chronic insomnia improvement
In adults with chronic insomnia, Lactium over 4 weeks improves both subjective sleep measures (insomnia severity, sleep quality scores, daytime sleepiness) and objective polysomnography measurements. Notable that the recent rigorous trial used objective sleep recording — many sleep supplements rely solely on self-report questionnaires. Reasonable consideration for adults with chronic insomnia, particularly when stress reactivity contributes to the sleep difficulty.
Sleep enhancement combined with L-theanine
Lactium and L-theanine act through complementary calming pathways — Lactium on GABA receptors, L-theanine on alpha brain waves and glutamate — and are sometimes combined in sleep formulas. This pairing is supportive rather than proven, as dedicated combination trials are limited. Reasonable to consider for sleep difficulties driven by an overactive mind.
Combined Zizyphus formulation for sleep
Lactium is sometimes combined with Zizyphus jujuba (for example, the LZComplex3 formulation), a traditional East Asian sleep botanical. Evidence for the combination is limited, so it is supportive rather than definitive. Reasonable to consider if you want a botanical pairing alongside Lactium.
Sleep disturbance — replicated in crossover trials
Multiple randomized crossover trials in different populations (including Korean adults) confirm Lactium's effect on sleep disturbance. Crossover designs provide robust within-subject evidence — each participant serves as their own control, which removes some of the noise from group-level comparisons. Strengthens the overall sleep evidence base across diverse populations rather than being tied to a single demographic or methodology.
Mechanism of action
GABA-A benzodiazepine site binding (unique peptide mechanism)
α-casozepine binds to the benzodiazepine binding site on GABA-A receptors, the same target as benzodiazepines such as diazepam (Valium) and alprazolam, showing benzodiazepine-like activity. It is unique in binding the benzodiazepine site without benzodiazepine side effects (no dependence, sedation, motor impairment, or cognitive impairment). This is the mechanism for safe daytime stress reduction plus evening sleep support.
Cortisol reduction
Reduces cortisol levels in response to stress. Mechanism via central effects on HPA axis through GABA-A modulation. Clinically meaningful for chronic stress states where elevated cortisol contributes to sleep problems and metabolic dysfunction.
Faster stress recovery (autonomic)
Faster autonomic recovery (BP, HR) after stressors has been demonstrated. Mechanism: GABA-A modulation reduces the duration of sympathetic nervous system activation. The practical benefit is faster physiological return to baseline after stressful events.
Tryptic hydrolysis releases active peptide
α-casozepine is naturally released during digestion of milk casein — explains observation of calmed infants after milk feeding. Lactium® manufactures the bioactive peptide via controlled tryptic hydrolysis of bovine αs1-casein. Mechanism: bypasses gastric digestion variability.
BBB penetration (small peptide)
Decapeptide size enables BBB crossing for direct CNS effects. Lipophilicity sufficient for passive transport. Mechanism for rapid onset (30-60 min) stress effects.
Combined synergy with L-theanine, Zizyphus, B6
Multiple clinical trials demonstrate Lactium synergy with: L-theanine (alpha-wave modulation), Zizyphus (saponin-mediated GABA effects), vitamin B6 (cofactor for GABA synthesis). Mechanism complementary to direct GABA-A modulation. Supports stack/combination protocols.
Clinical trials
Foundational pharmacological characterization (Miclo L, Perrin E, Driou A, Papadopoulos V, Boujrad N, Vanderesse R, Boudier JF, Desor D, Linden G, Gaillard JL 2001, FASEB J 15(10):1780-1782, doi:10.1096/fj.00-0685fje).
In vitro and animal pharmacological characterization of α-casozepine peptide identified from bovine αs1-casein tryptic hydrolysate.
Established α-casozepine as tryptic peptide from bovine αs1-CASEIN with benzodiazepine-like activity. Foundational discovery enabling subsequent clinical development of Lactium®. Demonstrated GABA-A receptor benzodiazepine site binding affinity.
Clinical hemodynamic stress response trial (Messaoudi M, Lefranc-Millot C, Desor D, Demagny B, Eur J Nutr 44(2):128-132, doi:10.1007/s00394-004-0534-7).
Healthy human volunteers facing successive mental and physical stress situations. Pre/post Lactium intake hemodynamic monitoring.
Lactium promoted faster stress recovery — lower blood pressure and heart rate during relaxation period (after stress) vs rest period (before stress induction). Demonstrated autonomic stress recovery benefits in healthy population. Foundational stress response evidence.
Randomized, double-blind, placebo-controlled trial (Chang CM, Tsai IJ, Yang CC, Liu WC, Yang CP 2024, Clinical Nutrition 43(12):275-284, doi:10.1016/j.clnu.2024.10.039, PMID 39541860).
Individuals with chronic insomnia. Lactium® (Alpha-s1 casein hydrolysate) vs placebo for 4 weeks. Subjective measures: ISI, GSDS, PSQI, ESS, HADS. Objective measures: polysomnography (PSG).
In 36 adults with chronic insomnia, 300 mg/day for 4 weeks significantly improved insomnia severity (ISI), sleep quality (GSDS, PSQI), daytime sleepiness (ESS), and mood (HADS), and polysomnography showed a reduced sleep onset latency (~7.7 minutes). Combining subjective questionnaires with objective polysomnography makes this a relatively rigorous chronic-insomnia trial.